Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 5Phase 3 2

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other 2Head & Neck 2Gastrointestinal 2Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Stomatitis 2Mucositis 2Mouth Neoplasms 2Head and Neck Neoplasms 2Neuroendocrine Tumors 1Lung Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × RRx-001 × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT05966194 2024-11-15

KEVLARx

EpicentRx, Inc.

Phase 2 Recruiting
216 enrolled
Head & NeckOther

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Stomatitis, Mucositis

NCT03515538 2024-11-04

PREVLAR

EpicentRx, Inc.

Phase 2 Completed
53 enrolled 15 charts
Head & NeckOther

Head and Neck Neoplasms, Mouth Neoplasms, Stomatitis, Mucositis

NCT02096354 2024-10-15

ROCKET

EpicentRx, Inc.

Phase 2 Completed
62 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

NCT02452970 2024-04-24

EPIC

EpicentRx, Inc.

Phase 2 Terminated
4 enrolled 6 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡